Goldman Sachs analyst Akinori Ueda initiated coverage of M3 Inc. with a Buy rating and 5,450 yen price target. Demand for the products and services offered by healthtech companies in Japan is transitioning to "stable expansion" after the pandemic fueled more rapid growth, said Ueda, who expects "solid" sales and operating profit growth from M3.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly